ConductScience.org, home

Paper1978477

Experiences of long-term treatment with remoxipride: efficacy and tolerability.

Wålinder J and 1 other. Acta Psychiatr Scand Suppl, 1990. Cited by 26 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Papers, record 1978477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1978477

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Experiences of long-term treatment with remoxipride: efficacy and tolerability.
PubMed
Journal
Acta Psychiatr Scand Suppl
PubMed
Year
1990
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.5
iCite
Revised in PubMed
2019-10-22
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wålinder JJ
2Holm ACA C

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antipsychotic AgentsMajor topic
BenzamidesMajor topic
SchizophreniaMajor topic
Schizophrenic PsychologyMajor topic
Adolescent
Adult
Aged
Chronic Disease
Double-Blind Method
Dyskinesia, Drug-Induced
Female
Haloperidol
Humans
Long-Term Care
Male
Middle Aged
Psychiatric Status Rating Scales
Remoxipride

Source PubMed

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
9,098,656Drug-induced movement disorders.Drug Saf1997https://conductscience.org/library/papers/9098656PubMed
8,935,806
Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?
Psychopharmacology (Berl)1996https://conductscience.org/library/papers/8935806PubMed
8,736,614Adverse effects of antipsychotic agents. Do newer agents offer advantages?Drugs1996https://conductscience.org/library/papers/8736614PubMed
8,329,149Tolerability of remoxipride in the long term treatment of schizophrenia. An overview.Drug Saf1993https://conductscience.org/library/papers/8329149PubMed
8,099,797Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease.J Neural Transm Gen Sect1993https://conductscience.org/library/papers/8099797PubMed
7,506,647Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.Drugs1993https://conductscience.org/library/papers/7506647PubMed
1,981,869Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.Drugs1990https://conductscience.org/library/papers/1981869PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1978477

GET https://conductscience.org/api/papers/v1/1978477/authors